NASDAQ:SKYE Skye Bioscience (SKYE) Stock Price, News & Analysis $4.17 -0.06 (-1.42%) (As of 10:10 AM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Skye Bioscience Stock (NASDAQ:SKYE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Key Stats Today's Range$4.15▼$4.3750-Day Range$3.14▼$6.0052-Week Range$1.44▼$19.41Volume38,746 shsAverage Volume176,071 shsMarket Capitalization$117.04 millionP/E RatioN/ADividend YieldN/APrice Target$18.67Consensus RatingBuy Company OverviewSkye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.Read More… Tesla Expert Shares His Bullish Thesis Inside a Free Ebook (Ad)Even though shares of Tesla are only up 3% this year, one man believes Tesla’s next bull run is just around the corner. In his professional opinion, the share price could reach $500 or more… Now, we understand that may seem far-fetched, but as you’ll see in his new ebook, it’s not as crazy as it may sound. In fact, he argues a Trump presidency could make it happen much faster than you might think. which is why we’re emailing you now… For the time being, he’s giving away his Tesla ebook for free. Inside explains how shares could reach $500 in the near future.To claim your copy, follow this link Skye Bioscience Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks30th Percentile Overall ScoreSKYE MarketRank™: Skye Bioscience scored higher than 30% of companies evaluated by MarketBeat, and ranked 834th out of 1,013 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingSkye Bioscience has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSkye Bioscience has only been the subject of 4 research reports in the past 90 days.Read more about Skye Bioscience's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Skye Bioscience are expected to decrease in the coming year, from ($1.06) to ($1.21) per share.Read more about Skye Bioscience's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.62% of the float of Skye Bioscience has been sold short.Short Interest Ratio / Days to CoverSkye Bioscience has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Skye Bioscience has recently increased by 7.08%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSkye Bioscience does not currently pay a dividend.Dividend GrowthSkye Bioscience does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.62% of the float of Skye Bioscience has been sold short.Short Interest Ratio / Days to CoverSkye Bioscience has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Skye Bioscience has recently increased by 7.08%, indicating that investor sentiment is decreasing significantly. News and Social Media1.9 / 5News SentimentN/A News SentimentSkye Bioscience has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Skye Bioscience this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for SKYE on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat Follows19 people have added Skye Bioscience to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Skye Bioscience insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,750,352.00 in company stock.Percentage Held by InsidersOnly 0.73% of the stock of Skye Bioscience is held by insiders.Percentage Held by InstitutionsOnly 21.09% of the stock of Skye Bioscience is held by institutions.Read more about Skye Bioscience's insider trading history. SKYE Stock News HeadlinesMarketBeat Week in Review – 10/7 - 10/11 (SKYE)Stocks delivered another winning week, but the latest inflation readings dampened hopes for aggressive rate cuts and turned attention toward earningsOctober 12, 2024 | marketbeat.comDon’t Sleep on Skye Bioscience—This Weight Loss Drug Could SoarSkye Bioscience has incredible potential upside, according to Wall Street analysts. It is striving to make a new weight loss drug, that could work with GLP-1s.October 9, 2024 | marketbeat.comAdd $2T of Potential Magic to Your PortfolioRevolutionizing a whole $2T entertainment and licensing industry might sound like the stuff of fairytales. But it’s very much within reach for a company with the rights to some of the highest grossing characters in history like Cinderella, Snow White, Peter Pan, and more. October 18, 2024 | Elf Labs (Ad)3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn't IgnoreCheck out these three micro-cap companies that have a big opportunity to succeed, but also significant a risk of failure.October 4, 2024 | marketbeat.comSkye Bioscience (NASDAQ:SKYE) Stock Quotes, Forecast and News SummaryOctober 11, 2024 | benzinga.comDon't Sleep on Skye Bioscience—This Weight Loss Drug Could SoarOctober 10, 2024 | benzinga.comLeo MillerOctober 9, 2024 | entrepreneur.comDon't Sleep on Skye Bioscience-This Weight Loss Drug Could SoarOctober 9, 2024 | msn.comSee More Headlines SKYE Stock Analysis - Frequently Asked Questions How have SKYE shares performed this year? Skye Bioscience's stock was trading at $2.72 at the beginning of 2024. Since then, SKYE shares have increased by 53.3% and is now trading at $4.17. View the best growth stocks for 2024 here. How were Skye Bioscience's earnings last quarter? Skye Bioscience, Inc. (NASDAQ:SKYE) announced its earnings results on Friday, August, 9th. The company reported ($0.20) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.20). How do I buy shares of Skye Bioscience? Shares of SKYE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Skye Bioscience own? Based on aggregate information from My MarketBeat watchlists, some other companies that Skye Bioscience investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Tesla (TSLA) and Alphabet (GOOG). Company Calendar Last Earnings8/09/2024Today10/18/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SKYE Previous SymbolNASDAQ:SKYE CUSIPN/A CIK1516551 Webskyebioscience.com Phone858-410-0266FaxN/AEmployees11Year FoundedN/APrice Target and Rating Average Stock Price Target$18.67 High Stock Price Target$25.00 Low Stock Price Target$14.00 Potential Upside/Downside+341.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,650,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-111.83% Return on Assets-80.69% Debt Debt-to-Equity RatioN/A Current Ratio6.07 Quick Ratio6.07 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.17) per share Price / Book-24.88Miscellaneous Outstanding Shares28,068,000Free Float29,428,000Market Cap$118.73 million OptionableOptionable Beta1.78 This page (NASDAQ:SKYE) was last updated on 10/18/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredAdd $2T of Potential Magic to Your PortfolioRevolutionizing a whole $2T entertainment and licensing industry might sound like the stuff of fairytales. But...Elf Labs | SponsoredDon’t Buy Another Stock Until Reading This…Buying stocks in today's market is a gamble… Unless you're using the right proven strategy! During my up...Unstoppable Prosperity | Sponsored3 Billionaires Dump Nvidia Shares. What Do They Know That You Don’t?Dan Ferris's research has been trusted by names at America's top investment banks, like JP Morgan and Barclays...Stansberry Research | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredWar on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adopti...Porter & Company | Sponsored320 hedge funds just sold this stock320 hedge funds just sold this stock A strange force has seized control of Wall Street. Hedge funds are alr...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding Skye Bioscience, Inc. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share Skye Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.